Diabetes Mellitus Type 2 Perspective

 
 
  • ENDO 2018 Read clinically focused news coverage of key developments from ENDO 2018.
  • ENDO 2018: What to Expect It's a meeting where nobodies rub elbows with somebodies, camaraderie is created, and the quantity of ideas proves that endocrinologists are 'pretty worthy people,' says Dr Richard Plotzker.
  • The State of the Art in Cardiovascular Risk Reduction Dr Williams provides an overview of the latest information on cardiovascular risk reduction, from the American College of Cardiology.
  • Alcohol Advice Demands Full Disclosure First What do you tell patients who ask about 'safe' alcohol intake--or who inquire about your own drinking habits?
  • Five Reasons to Avoid Going Gluten-Free Emerging evidence suggests that significant costs--physical and financial--are associated with this diet if not administered properly.
  • Which CGM for Which Diabetes Patient?   Dr Peters clarifies the pros and cons of the Dexcom and FreeStyle Libre continuous glucose monitors for patients with diabetes.
  • The Future of Medicine, From a Leader in Venture Capital   The founder of Sun Microsystems predicted that artificial intelligence will replace 80% of physicians, but he says the profession could fortify itself by changing its focus.
  • 'Game Changer': Treat Diabetes and Also Reduce CV Risk   Drs Shubrook and Chamberlain discuss cardiovascular risk reduction associated with SGLT-2 inhibitors and GLP-1 agonists in T2D, and advise clinicians to 'be aware.'
  • Artificial Intelligence in Cardiology: Friend or Foe?   Dr Turakhia reassures Dr Mandrola that true AI learns 'on the job' and will be a lot better than current computer-read ECGs.
  • What Comes After Metformin in Type 2 Diabetes? Choosing the right drug for the right patient can affect glycemic control and mortality outcomes.
  • Defending the Cornerstones of Endocrinology The government's recent 'ban' on seven science words prompted endocrinologist Richard Plotzker to reflect on their significance in medicine and especially in the field of endocrinology.
  • New Diabetes Guidelines Fail to Guide   An effort to encourage individualized treatment choices may muddy the therapy waters, says Dr Peters.
  • Spotlight on Retinal Diseases New anti-VEGF therapies for DME and AMD, as well as retinal detachment outcomes, were among the highlights presented at Retina Subspecialty Day during AAO 2017.
  • Type 2 Diabetes in Kids: Don't Miss It   Dr Tyree Winters stresses the importance of identifying at-risk kids and screening often, as much as annually, to be sure that early-stage type 2 diabetes is not missed.
  • What Cardiologists Need to Know About New Diabetes Drugs   Drs O'Donoghue and McGuire discuss the data on the various SGLT2 inhibitors and GLP1 receptor agonists and when to consider prescribing them to your patients with diabetes.
  • Diabetes Medications: Deprescribe Them in the Elderly? A new set of guidelines and an algorithm help clinicians decide when to pull back on antihyperglycemic drugs, including insulin.
  • Are Older Diabetes Drugs Safe and Effective?   You might have to prescribe older diabetes drugs to some patients so that they will be able to maintain treatment.
  • Ongoing Trials Put Focus Back on Fatty Liver Disease Researchers at this year's Liver Meeting offered promising insights into nonalcoholic steatohepatitis and fatty liver disease. Dr William Balistreri surveys their results.
  • ADA 2018 Abridged Standards: Update for Primary Care   What are the key changes in the 2018 ADA Abridged Standards for Diabetes Care that primary care clinicians should know?
  • National Diabetes Prevention Program: What You Need to Know   A new program cuts the risk of prediabetes progressing to type 2 diabetes by nearly 60%.